APLS vs. IONS, BPMC, ELAN, CYTK, JAZZ, OGN, VKTX, ITCI, BBIO, and MDGL
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Jazz Pharmaceuticals (JAZZ), Organon & Co. (OGN), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), BridgeBio Pharma (BBIO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "pharmaceutical preparations" industry.
Apellis Pharmaceuticals (NASDAQ:APLS) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk.
In the previous week, Apellis Pharmaceuticals had 16 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 21 mentions for Apellis Pharmaceuticals and 5 mentions for Ionis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.51 beat Ionis Pharmaceuticals' score of 0.21 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media.
Ionis Pharmaceuticals received 364 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. However, 67.24% of users gave Apellis Pharmaceuticals an outperform vote while only 60.09% of users gave Ionis Pharmaceuticals an outperform vote.
96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 7.5% of Apellis Pharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Ionis Pharmaceuticals has higher revenue and earnings than Apellis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Apellis Pharmaceuticals has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
Apellis Pharmaceuticals presently has a consensus price target of $77.93, indicating a potential upside of 54.45%. Ionis Pharmaceuticals has a consensus price target of $56.08, indicating a potential upside of 32.92%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Apellis Pharmaceuticals is more favorable than Ionis Pharmaceuticals.
Ionis Pharmaceuticals has a net margin of -46.32% compared to Apellis Pharmaceuticals' net margin of -133.34%. Ionis Pharmaceuticals' return on equity of -90.29% beat Apellis Pharmaceuticals' return on equity.
Summary
Apellis Pharmaceuticals beats Ionis Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
